1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Lilly Wows ADA Crowd With Obesity Data Across Three-Drug Incretin Portfolio

Weight Loss Of Up To 24.2% With ‘Triple G’ Retatrutide

 
• By Mandy Jackson

Lilly may gain its first US approval in obesity with Mounjaro before the end of 2023, but presented data at ADA for it and two other drugs – retatrutide and orforglipron – that also yielded significant weight loss.

Black and white scale on wood floor
Lilly presented data at ADA on three obesity drugs • Source: Shutterstock

Eli Lilly and Company is a few years behind Novo Nordisk A/S in bringing a GLP-1 agonist to market for obesity, but it presented data at the American Diabetes Association (ADA) annual meeting that could give the company a best-in-class portfolio of medicines, including its GLP-1/GIP/glucagon receptor (GGG) triagonist retatrutide, which generated weight loss of up to 24.2% in overweight and obese patients without diabetes at 48 weeks in a Phase II clinical trial presented on 26 June.

Novo Nordisk already markets the injectable GLP-1 agonist Wegovy (semaglutide) for obesity in the US and plans to submit its high-dose oral version of semaglutide for US and EU approvals this year based on the Phase III OASIS 1 trial, which was presented on 25 June at ADA in San Diego. (Also see "With Competition Closing In, Novo Details Oral Semaglutide Weight Loss At ADA" - Scrip, 26 June, 2023

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

More from R&D

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.